Grantham, Mayo, Van Otterloo & Co (GMO)’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Grantham, Mayo, Van Otterloo & Co (GMO)'s NVS Position: Q3 2026 in Review
Grantham, Mayo, Van Otterloo & Co (GMO) increased its Novartis (NVS) stake by 15% in Q3 2026, buying an estimated $5.42M and bringing the position to 281,714 shares worth $40.2M. The position accounts for 0.09% of the portfolio, ranked #95.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NVS in Q2 2018 and has held it in 25 quarters since. The position peaked at $186M in Q3 2023. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) held 281,714 shares of Novartis worth $40.2M as of Q3 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) bought 35,757 Novartis shares in Q3 2026, an estimated $5.42M.
- Novartis made up 0.09% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q3 2026, its #95 holding.
- Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Novartis in Q2 2018 and has held it in 25 quarters since.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s Novartis position peaked at $186M in Q3 2023.
- 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.
Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2026, filed 13 Nov 2026.